Business
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
WESTMINSTER, Colo., August 28, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the follo
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"WESTMINSTER, Colo., August 28, 2025--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in September:","length":576,"tagName":"p"},{"type":"text","content":"Cantor Global Healthcare Conference 2025 in New York, NYManagement will participate in one-on-one meetings and participate in a fireside chat on Friday, September 5, at 9:35 a.m. ET. Click here for a link to the live webcast.","length":226,"tagName":"p"},{"type":"text","content":"Lake Street Capital Markets 9th Annual Best Ideas Growth Conference in New York, NYManagement will participate in one-on-one meetings on Thursday, September 11.","length":161,"tagName":"p"},{"type":"text","content":"A webcast replay of the fireside chat will be available for 90 days following the presentation in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.","length":187,"tagName":"p"},{"type":"text","content":"About TriSalus Life SciencesTriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that d...